Rapalogs in cancer prevention

References

• Hitt R, Young-Xu Y, Silver M, Perls T. Centenarians: the older you get, the healthier you have been. Lancet 1999; 354:652; http://dx.doi.org/10.1016/S0140-6736(99)01987-X; PMID: 10466675
   PubMed Web of Science ®Google Scholar
• Evert J, Lawler E, Bogan H, Perls T. Morbidity profiles of centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci Med Sci 2003; 58:232 - 7; http://dx.doi.org/10.1093/gerona/58.3.M232; PMID: 12634289
   PubMed Web of Science ®Google Scholar
• Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT. Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. J Gerontol A Biol Sci Med Sci 2012; 67:395 - 405; http://dx.doi.org/10.1093/gerona/glr223; PMID: 22219514
   PubMed Web of Science ®Google Scholar
• Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci 2003; 58:291 - 6; http://dx.doi.org/10.1093/gerona/58.4.B291; PMID: 12663691
   PubMed Web of Science ®Google Scholar
• Buffenstein R. The naked mole-rat: a new long-living model for human aging research. J Gerontol A Biol Sci Med Sci 2005; 60:1369 - 77; http://dx.doi.org/10.1093/gerona/60.11.1369; PMID: 16339321
   PubMed Web of Science ®Google Scholar
• Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science 2010; 328:321 - 6; http://dx.doi.org/10.1126/science.1172539; PMID: 20395504
   PubMed Web of Science ®Google Scholar
• Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol Sci 2010; 31:89 - 98; http://dx.doi.org/10.1016/j.tips.2009.11.004; PMID: 20097433
   PubMed Web of Science ®Google Scholar
• Sharp ZD. Aging and TOR: interwoven in the fabric of life. Cell Mol Life Sci 2011; 68:587 - 97; http://dx.doi.org/10.1007/s00018-010-0542-0; PMID: 20960025
   PubMed Web of Science ®Google Scholar
• Minor RK, Allard JS, Younts CM, Ward TM, de Cabo R. Dietary interventions to extend life span and health span based on calorie restriction. J Gerontol A Biol Sci Med Sci 2010; 65:695 - 703; http://dx.doi.org/10.1093/gerona/glq042; PMID: 20371545
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell Death Dis 2010; 1:e12; http://dx.doi.org/10.1038/cddis.2009.17; PMID: 21364614
   PubMedGoogle Scholar
• Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010; 9:683 - 8; http://dx.doi.org/10.4161/cc.9.4.10766; PMID: 20139716
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY) 2011; 3:1051 - 62; PMID: 22166724
   PubMedGoogle Scholar
• Ye J, Keller JN. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. Aging (Albany NY) 2010; 2:361 - 8; PMID: 20606248
   PubMedGoogle Scholar
• Soare A, Cangemi R, Omodei D, Holloszy JO, Fontana L. Long-term calorie restriction, but not endurance exercise, lowers core body temperature in humans. Aging (Albany NY) 2011; 3:374 - 9; PMID: 21483032
   PubMedGoogle Scholar
• Blagosklonny MV. NCI’s provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011; 2:1352 - 67; PMID: 22267462
   PubMed Web of Science ®Google Scholar
• Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol 2006; 16:206 - 12; http://dx.doi.org/10.1016/j.tcb.2006.02.002; PMID: 16516475
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471 - 84; http://dx.doi.org/10.1016/j.cell.2006.01.016; PMID: 16469695
   PubMed Web of Science ®Google Scholar
• Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23:744 - 55; http://dx.doi.org/10.1016/j.ceb.2011.09.003; PMID: 21963299
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Hall MN. Growth and aging: a common molecular mechanism. Aging (Albany NY) 2009; 1:357 - 62, 20; PMID: 20157523
   PubMedGoogle Scholar
• Blagosklonny MV. Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program. Cell Cycle 2010; 9:3151 - 6; http://dx.doi.org/10.4161/cc.9.16.13120; PMID: 20724817
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives. Aging (Albany NY) 2010; 2:265 - 73; PMID: 20519781
   PubMedGoogle Scholar
• Blagosklonny MV. Why the disposable soma theory cannot explain why women live longer and why we age. Aging (Albany NY) 2010; 2:884 - 7; PMID: 21191147
   PubMedGoogle Scholar
• Blagosklonny MV. Rapamycin and quasi-programmed aging: four years later. Cell Cycle 2010; 9:1859 - 62; http://dx.doi.org/10.4161/cc.9.10.11872; PMID: 20436272
   PubMed Web of Science ®Google Scholar
• Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 2006; 20:174 - 84; http://dx.doi.org/10.1101/gad.1381406; PMID: 16418483
   PubMed Web of Science ®Google Scholar
• Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35 - 46; http://dx.doi.org/10.1016/j.cmet.2009.11.010; PMID: 20074526
   PubMed Web of Science ®Google Scholar
• Moskalev AA, Shaposhnikov MV. Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster. Rejuvenation Res 2010; 13:246 - 7; http://dx.doi.org/10.1089/rej.2009.0903; PMID: 20017609
   PubMed Web of Science ®Google Scholar
• Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392 - 5; PMID: 19587680
   PubMed Web of Science ®Google Scholar
• Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66:191 - 201; http://dx.doi.org/10.1093/gerona/glq178; PMID: 20974732
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011; 10:4230 - 6; http://dx.doi.org/10.4161/cc.10.24.18486; PMID: 22107964
   PubMed Web of Science ®Google Scholar
• Khanna A, Kapahi P. Rapamycin: killing two birds with one stone. Aging (Albany NY) 2011; 3:1043 - 4; PMID: 22170738
   PubMedGoogle Scholar
• Longo VD, Fontana L. Intermittent supplementation with rapamycin as a dietary restriction mimetic. Aging (Albany NY) 2011; 3:1039 - 40; PMID: 22147496
   PubMedGoogle Scholar
• Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, et al. Rapamycin slows aging in mice. Aging Cell 2012; 11:675 - 82; http://dx.doi.org/10.1111/j.1474-9726.2012.00832.x; PMID: 22587563
   PubMed Web of Science ®Google Scholar
• Spong A, Bartke A. Rapamycin slows aging in mice. Cell Cycle 2012; 11:845; http://dx.doi.org/10.4161/cc.11.5.19607; PMID: 22356747
   PubMed Web of Science ®Google Scholar
• Kaeberlein M, Powers RW 3rd, Steffen KK, Westman EA, Hu D, Dang N, et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 2005; 310:1193 - 6; http://dx.doi.org/10.1126/science.1115535; PMID: 16293764
   PubMed Web of Science ®Google Scholar
• Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004; 14:885 - 90; http://dx.doi.org/10.1016/j.cub.2004.03.059; PMID: 15186745
   PubMed Web of Science ®Google Scholar
• Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140 - 4; http://dx.doi.org/10.1126/science.1177221; PMID: 19797661
   PubMed Web of Science ®Google Scholar
• Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. The TOR pathway comes of age. Biochim Biophys Acta 2009; 1790:1067 - 74; http://dx.doi.org/10.1016/j.bbagen.2009.06.007; PMID: 19539012
   PubMed Web of Science ®Google Scholar
• Lee JH, Bodmer R, Bier E, Karin M. Sestrins at the crossroad between stress and aging. Aging (Albany NY) 2010; 2:369 - 74; PMID: 20606249
   PubMedGoogle Scholar
• Ha CW, Huh WK. The implication of Sir2 in replicative aging and senescence in Saccharomyces cerevisiae. Aging (Albany NY) 2011; 3:319 - 24; PMID: 21415463
   PubMedGoogle Scholar
• Pani G. P66SHC and ageing: ROS and TOR?. Aging (Albany NY) 2010; 2:514 - 8; PMID: 20689155
   PubMedGoogle Scholar
• Stipp D. A new path to longevity. Sci Am 2012; 306:32 - 9; http://dx.doi.org/10.1038/scientificamerican0112-32; PMID: 22279832
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Cell cycle arrest is not senescence. Aging (Albany NY) 2011; 3:94 - 101; PMID: 21297220
   PubMedGoogle Scholar
• Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355 - 61; http://dx.doi.org/10.4161/cc.7.21.6919; PMID: 18948731
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896 - 900; http://dx.doi.org/10.4161/cc.8.12.8809; PMID: 19478560
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany, NY Online) 2010; 2:892 - 3
   PubMedGoogle Scholar
• Wesierska-Gadek J. mTOR and its link to the picture of Dorian Gray—reactivation of mTOR promotes aging. Aging 2010; 2:924 - 35; PMID: 21212465
   PubMedGoogle Scholar
• Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012; 11:2391 - 401; http://dx.doi.org/10.4161/cc.20683; PMID: 22627671
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009; 8:1883 - 7; http://dx.doi.org/10.4161/cc.8.12.8815; PMID: 19448395
   PubMed Web of Science ®Google Scholar
• Gems DH, Guardia YD. Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction?. Antioxid Redox Signal 2012; http://dx.doi.org/10.1089/ars.2012.4840; PMID: 22870907
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. TOR-driven aging: speeding car without brakes. Cell Cycle 2009; 8:4055 - 9; http://dx.doi.org/10.4161/cc.8.24.10310; PMID: 19923900
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Prospective treatment of age-related diseases by slowing down aging. Am J Pathol 2012; 181:1142 - 6; http://dx.doi.org/10.1016/j.ajpath.2012.06.024; PMID: 22841821
   PubMed Web of Science ®Google Scholar
• Bjedov I, Partridge L. A longer and healthier life with TOR down-regulation: genetics and drugs. Biochem Soc Trans 2011; 39:460 - 5; http://dx.doi.org/10.1042/BST0390460; PMID: 21428920
   PubMed Web of Science ®Google Scholar
• Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol 2012; 22:R741 - 52; http://dx.doi.org/10.1016/j.cub.2012.07.024; PMID: 22975005
   PubMed Web of Science ®Google Scholar
• Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell 2012; 11:326 - 35; http://dx.doi.org/10.1111/j.1474-9726.2011.00791.x; PMID: 22212527
   PubMed Web of Science ®Google Scholar
• Tacutu R, Budovsky A, Yanai H, Fraifeld VE. Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective. Aging (Albany NY) 2011; 3:1178 - 91; PMID: 22184282
   PubMedGoogle Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789 - 99; http://dx.doi.org/10.1038/nm1087; PMID: 15286780
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70; http://dx.doi.org/10.1016/S0092-8674(00)81683-9; PMID: 10647931
   PubMed Web of Science ®Google Scholar
• Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002; 13:2276 - 88; http://dx.doi.org/10.1091/mbc.01-12-0584; PMID: 12134068
   PubMed Web of Science ®Google Scholar
• Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007; 12:487 - 502; http://dx.doi.org/10.1016/j.devcel.2007.03.020; PMID: 17419990
   PubMed Web of Science ®Google Scholar
• Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13:252 - 9; http://dx.doi.org/10.1016/j.molmed.2007.04.002; PMID: 17452018
   PubMed Web of Science ®Google Scholar
• Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40:310 - 22; http://dx.doi.org/10.1016/j.molcel.2010.09.026; PMID: 20965424
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21 - 35; http://dx.doi.org/10.1038/nrm3025; PMID: 21157483
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Darzynkiewicz Z. Four birds with one stone: RAPA as potential anticancer therapy. Cancer Biol Ther 2002; 1:359 - 61; http://dx.doi.org/10.4161/cbt.1.4.6; PMID: 12432246
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther 2003; 2:Suppl 1 S169 - 77; PMID: 14508096
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6:184 - 92; http://dx.doi.org/10.1038/nrc1819; PMID: 16453012
   PubMed Web of Science ®Google Scholar
• Dbouk HA, Backer JM. A beta version of life: p110β takes center stage. Oncotarget 2010; 1:729 - 33; PMID: 21321382
   PubMed Web of Science ®Google Scholar
• Hart JR, Vogt PK. Phosphorylation of AKT: a mutational analysis. Oncotarget 2011; 2:467 - 76; PMID: 21670491
   PubMed Web of Science ®Google Scholar
• Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer?. Oncotarget 2011; 2:1314 - 21; PMID: 22248929
   PubMed Web of Science ®Google Scholar
• Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, et al. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells. Cancer Biol Ther 2012; 13:34 - 42; http://dx.doi.org/10.4161/cbt.13.1.18437; PMID: 22336586
   PubMed Web of Science ®Google Scholar
• Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget 2010; 1:530 - 43; PMID: 21317449
   PubMed Web of Science ®Google Scholar
• Major P. Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 2011; 3:189 - 91; PMID: 21415462
   PubMedGoogle Scholar
• Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1:89 - 103; PMID: 20671809
   PubMed Web of Science ®Google Scholar
• Li H, Gao Q, Guo L, Lu SH. The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 2011; 11:950 - 8; http://dx.doi.org/10.4161/cbt.11.11.15531; PMID: 21467840
   PubMed Web of Science ®Google Scholar
• Barger JF, Gallo CA, Torni KA, Merk L, Seibel WL, Nelson S, et al. Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to rapamycin. Cancer Biol Ther 2011; 10:1256 - 61; PMID: 20935504
   PubMed Web of Science ®Google Scholar
• Schmidt-Kittler O, Zhu J, Yang J, Liu G, Hendricks W, Lengauer C, et al. PI3Kα inhibitors that inhibit metastasis. Oncotarget 2010; 1:339 - 48; PMID: 21179398
   PubMed Web of Science ®Google Scholar
• Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, et al. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2011; 2:538 - 50; PMID: 21730367
   PubMed Web of Science ®Google Scholar
• Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006; 5:1065 - 73; http://dx.doi.org/10.4161/cbt.5.9.3175; PMID: 16969122
   PubMed Web of Science ®Google Scholar
• Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833 - 49; PMID: 22064833
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 2005; 102:8204 - 9; http://dx.doi.org/10.1073/pnas.0502857102; PMID: 15928081
   PubMed Web of Science ®Google Scholar
• Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 2006; 20:267 - 75; http://dx.doi.org/10.1101/gad.1363206; PMID: 16452501
   PubMed Web of Science ®Google Scholar
• Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, et al. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 2009; 8:4168 - 75; http://dx.doi.org/10.4161/cc.8.24.10800; PMID: 20054236
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A 2010; 107:9660 - 4; http://dx.doi.org/10.1073/pnas.1002298107; PMID: 20457898
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Gudkov AV, Blagosklonny MV. Weak p53 permits senescence during cell cycle arrest. Cell Cycle 2010; 9:4323 - 7; http://dx.doi.org/10.4161/cc.9.21.13584; PMID: 21051933
   PubMed Web of Science ®Google Scholar
• Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY). 2010;2:344-352.
   Google Scholar
• Blagosklonny MV. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors. Cell Cycle 2011; 10:2295 - 8; http://dx.doi.org/10.4161/cc.10.14.16819; PMID: 21715978
   PubMed Web of Science ®Google Scholar
• Maki CG. Decision-making by p53 and mTOR. Aging (Albany NY) 2010; 2:324 - 6; PMID: 20603526
   PubMedGoogle Scholar
• Serrano M. Shifting senescence into quiescence by turning up p53. Cell Cycle 2010; 9:4256 - 7; http://dx.doi.org/10.4161/cc.9.21.13785; PMID: 20980826
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z. Another “Janus paradox” of p53: induction of cell senescence versus quiescence. Aging (Albany NY) 2010; 2:329 - 30; PMID: 20603525
   PubMedGoogle Scholar
• Galluzzi L, Kepp O, Kroemer G. TP53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535 - 7; PMID: 20876940
   PubMedGoogle Scholar
• Chao SK, Horwitz SB, McDaid HM. Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence. Oncotarget 2011; 2:89 - 98; PMID: 21399233
   PubMed Web of Science ®Google Scholar
• Lane DP, Verma C, Fang CC. The p53 inducing drug dosage may determine quiescence or senescence. Aging (Albany NY) 2010; 2:748; PMID: 21068468
   PubMedGoogle Scholar
• Poyurovsky MV, Prives C. P53 and aging: A fresh look at an old paradigm. Aging (Albany NY) 2010; 2:380 - 2; PMID: 20657036
   PubMedGoogle Scholar
• Vigneron A, Vousden KH. p53, ROS and senescence in the control of aging. Aging (Albany NY) 2010; 2:471 - 4; PMID: 20729567
   PubMedGoogle Scholar
• Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130 - 41; PMID: 22246147
   PubMedGoogle Scholar
• Blagosklonny MV. Oncogenic resistance to growth-limiting conditions. Nat Rev Cancer 2002; 2:221 - 5; http://dx.doi.org/10.1038/nrc743; PMID: 11990858
   PubMed Web of Science ®Google Scholar
• Greaves M. Leukemogenesis and ageing: 'fit for transformation'?. Aging (Albany, NY Online) 2011; 3:79 - 80
   PubMedGoogle Scholar
• Henry CJ, Marusyk A, DeGregori J. Aging-associated changes in hematopoiesis and leukemogenesis: what’s the connection?. Aging (Albany NY) 2011; 3:643 - 56; PMID: 21765201
   PubMedGoogle Scholar
• Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13 - 7; http://dx.doi.org/10.1016/S1535-6108(03)00336-2; PMID: 14749122
   PubMed Web of Science ®Google Scholar
• Garber K. Rapamycin’s resurrection: a new way to target the cancer cell cycle. J Natl Cancer Inst 2001; 93:1517 - 9; http://dx.doi.org/10.1093/jnci/93.20.1517; PMID: 11604470
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335 - 48; http://dx.doi.org/10.1038/nrc1362; PMID: 15122205
   PubMed Web of Science ®Google Scholar
• Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell 2006; 9:77 - 9; http://dx.doi.org/10.1016/j.ccr.2006.01.021; PMID: 16473275
   PubMed Web of Science ®Google Scholar
• Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15:428 - 35; http://dx.doi.org/10.1634/theoncologist.2009-0178; PMID: 20332142
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al, Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271 - 81; http://dx.doi.org/10.1056/NEJMoa066838; PMID: 17538086
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510 - 7; PMID: 21680954
   PubMed Web of Science ®Google Scholar
• Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom’s Macroglobulinemia. Oncotarget 2010; 1:578 - 82; PMID: 21317453
   PubMed Web of Science ®Google Scholar
• Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 2012; 181:278 - 93; http://dx.doi.org/10.1016/j.ajpath.2012.03.017; PMID: 22698676
   PubMed Web of Science ®Google Scholar
• Lewis DA, Travers JB, Machado C, Somani AK, Spandau DF. Reversing the aging stromal phenotype prevents carcinoma initiation. Aging (Albany NY) 2011; 3:407 - 16; PMID: 21515933
   PubMedGoogle Scholar
• Smit MA, Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY) 2010; 2:735 - 41; PMID: 20975209
   PubMedGoogle Scholar
• Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446 - 9; http://dx.doi.org/10.1111/j.1399-0012.2004.00188.x; PMID: 15233824
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317 - 23; http://dx.doi.org/10.1056/NEJMoa042831; PMID: 15800227
   PubMed Web of Science ®Google Scholar
• Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581 - 9; http://dx.doi.org/10.1681/ASN.2005090993; PMID: 16434506
   PubMed Web of Science ®Google Scholar
• Cullis B, D’Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47:e67 - 72; http://dx.doi.org/10.1053/j.ajkd.2006.01.029; PMID: 16632009
   PubMedGoogle Scholar
• Yakupoglu YK, Buell JF, Woodle S, Kahan BD. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 2006; 38:358 - 61; http://dx.doi.org/10.1016/j.transproceed.2006.01.019; PMID: 16549120
   PubMed Web of Science ®Google Scholar
• Zmonarski SC, Boratyńska M, Rabczyński J, Kazimierczak K, Klinger M. Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 2005; 37:964 - 6; http://dx.doi.org/10.1016/j.transproceed.2004.12.172; PMID: 15848592
   PubMed Web of Science ®Google Scholar
• Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007; 13:2281 - 9; http://dx.doi.org/10.1158/1078-0432.CCR-06-2570; PMID: 17404113
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007; 67:2408 - 13; http://dx.doi.org/10.1158/0008-5472.CAN-06-4490; PMID: 17363557
   PubMed Web of Science ®Google Scholar
• Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Mol Cancer Ther 2007; 6:2188 - 97; http://dx.doi.org/10.1158/1535-7163.MCT-07-0235; PMID: 17699716
   PubMed Web of Science ®Google Scholar
• Checkley LA, Rho O, Moore T, Hursting S, DiGiovanni J. Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Prev Res (Phila) 2011; 4:1011 - 20; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0375; PMID: 21733825
   PubMed Web of Science ®Google Scholar
• Robinson J, Lai C, Martin A, Nye E, Tomlinson I, Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. J Pathol 2009; 219:35 - 40; http://dx.doi.org/10.1002/path.2562; PMID: 19434632
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol 2010; 176:2092 - 7; http://dx.doi.org/10.2353/ajpath.2010.091050; PMID: 20363920
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520 - 4; http://dx.doi.org/10.4161/cbt.7.10.6663; PMID: 18769112
   PubMed Web of Science ®Google Scholar
• Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice. Aging (Albany, NY Online) 2012; 4
   Google Scholar
• Berrigan D, Perkins SN, Haines DC, Hursting SD. Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-deficient mice. Carcinogenesis 2002; 23:817 - 22; http://dx.doi.org/10.1093/carcin/23.5.817; PMID: 12016155
   PubMed Web of Science ®Google Scholar
• Hursting SD, Perkins SN, Phang JM. Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 1994; 91:7036 - 40; http://dx.doi.org/10.1073/pnas.91.15.7036; PMID: 8041741
   PubMed Web of Science ®Google Scholar
• Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM. Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. Cancer Res 1997; 57:2843 - 6; PMID: 9230186
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5:2087 - 102; http://dx.doi.org/10.4161/cc.5.18.3288; PMID: 17012837
   PubMed Web of Science ®Google Scholar
• Kolosova NG, Muraleva NA, Zhdankina AA, Stefanova NA, Fursova AZ, Blagosklonny MV. Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol 2012; 181:472 - 7; http://dx.doi.org/10.1016/j.ajpath.2012.04.018; PMID: 22683466
   PubMed Web of Science ®Google Scholar
• Yang SB, Tien AC, Boddupalli G, Xu AW, Jan YN, Jan LY. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 2012; 75:425 - 36; http://dx.doi.org/10.1016/j.neuron.2012.03.043; PMID: 22884327
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. Cell Cycle 2010; 9:4788 - 94; http://dx.doi.org/10.4161/cc.9.24.14360; PMID: 21150328
   PubMed Web of Science ®Google Scholar
• Sherif ZA, Sultan AS. Divergent control of Cav-1 expression in non-cancerous Li-Fraumeni syndrome and human cancer cell lines. Cancer Biol Ther 2012; 14:11; PMID: 23114650
   PubMed Web of Science ®Google Scholar
• Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010; 1:405 - 22; PMID: 21311097
   PubMed Web of Science ®Google Scholar
• Glazer RI, et al. A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53. Oncotarget 2010; 1:470 - 1; PMID: 21317445
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Novel strategies of protecting non-cancer cells during chemotherapy: are they ready for clinical testing?. Oncotarget 2011; 2:107 - 8; PMID: 21487161
   PubMedGoogle Scholar
• van Leeuwen IM, Laín S. Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs. Oncotarget 2011; 2:274 - 6; PMID: 21512204
   PubMed Web of Science ®Google Scholar
• Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB, et al. mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 2012; 11:401 - 14; http://dx.doi.org/10.1016/j.stem.2012.06.007; PMID: 22958932
   PubMed Web of Science ®Google Scholar
• Iglesias-Bartolome R, Gutkind JS. Exploiting the mTOR paradox for disease prevention. Oncotarget 2012; 3:1061 - 3; PMID: 23085637
   PubMedGoogle Scholar
• Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY) 2009; 1:988 - 1007; PMID: 20157582
   PubMedGoogle Scholar
• Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res 2010; 70:1564 - 72; http://dx.doi.org/10.1158/0008-5472.CAN-09-3228; PMID: 20145127
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle 2010; 9:4474 - 6; http://dx.doi.org/10.4161/cc.9.22.13954; PMID: 21088487
   PubMed Web of Science ®Google Scholar
• Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 2012; 4:24ra27; http://dx.doi.org/10.1126/scitranslmed.3003293; PMID: 22323820
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 2005; 12:592 - 602; http://dx.doi.org/10.1038/sj.cdd.4401610; PMID: 15818400
   PubMed Web of Science ®Google Scholar